Advertisement

biote Corp. BTMD

Set alert

Price alert · BTMD

All alert types
1.11 USD -0.06 -5.13%

At close · Oct 30

1.13 +0.02 +1.80%

After hours · Oct 30, 4:00 PM ET

Bid
1.11 × 2
Ask
1.12 × 2
1.11 Day range 1.20
1.00 52-week range 2.98
YTD
-57.31%
1 year
-60.07%
Open
1.17
Prev close
1.17
Mkt cap
37.63M
Vol
62.19K
Avg vol
204.43K
EPS
0.14
P/E
7.93
Div yield
0.00%
More statistics
Low
1.11
High
1.20
Forward P/E
9.98
Beta
0.00
Short ratio
3.73
Inst. own
64.60%
Dividend
0.00
Ex-div date
Earnings
Aug 8, 2024
50-d avg
5.88
200-d avg
6.21
1y target
9.95

3M chart

Chart tools
Interval

Signals (16)
NameDateAgo
SMA: BearishOct 30, 20262 days ago
SMA: BullishOct 29, 20263 days ago
RSI: OversoldOct 13, 20262 weeks ago
MACD: Buy SignalOct 8, 20263 weeks ago
MACD: Sell SignalOct 1, 20261 month ago
RSI: OversoldOct 1, 20261 month ago
MACD: Buy SignalSep 30, 20261 month ago
MACD: Sell SignalSep 24, 20261 month ago
MACD: Buy SignalSep 18, 20261 month ago
MACD: Sell SignalSep 11, 20261 month ago
MACD: Buy SignalAug 25, 20262 months ago
RSI: OversoldAug 17, 20262 months ago
RSI: OversoldAug 12, 20262 months ago
RSI: OversoldAug 7, 20262 months ago
SMA: BearishAug 6, 20262 months ago
SMA: BearishAug 6, 20262 months ago

Key statistics

Market cap
305.42M
Enterprise value
287.07M
Trailing P/E
19.30
Forward P/E
9.98
PEG ratio
0.00
Price / sales
1.58
Price / book
0.00
EPS (TTM)
0.30
Beta
0.00
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
3.72%
Revenue (TTM)
193.06M
Revenue growth
12.80%
Free cash flow
37.61M
Total cash
38.23M
Total debt
122.31M
Return on equity
0.00%
Shares outstanding
31.11M
Short % of float
3.21%
50-day average
5.88
200-day average
6.21

Analyst view

Consensus: strong buy

Strong buy
Price target (mean) 9.95 +796.1% upside
Target (low)
8.00
Target (mean)
9.95
Target (high)
12.00
Ratings (0m) 6 6 buy · 0 hold · 0 sell
  • Strong buy1
  • Buy5
  • Hold0
  • Sell0
  • Strong sell0

Next earnings

Aug 8, 2024

Expected Aug 8, 2024. Consensus EPS estimate 0.17.

Earnings history

Financials — quick view

All financials
BTMD Revenue — quarterly 44.23M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
BTMD Net income — quarterly -6.56M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
BTMD EPS — quarterly -0.23
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026

Earnings

BTMD recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 12, 2024Sep 1, 20240.090.33+0.24+266.67%
Aug 8, 2024Jun 1, 20240.090.14+0.05+55.56%
Aug 8, 2024Jun 1, 20240.09———
May 7, 2024Mar 1, 20240.050.23+0.18+360.00%
May 7, 2024Mar 1, 20240.05———
Mar 12, 2024Dec 1, 20230.08———

Upgrades / downgrades

BTMD analyst upgrades and downgrades
DateFirmActionFromTo
Dec 16, 2024Craig-Halluminit—Buy
Mar 13, 2024Roth MKMreitBuyBuy
Feb 20, 2024B. Riley Securitiesinit—Buy
Feb 1, 2024Jefferiesinit—Buy
Jan 18, 2024Truist SecuritiesmainBuyBuy
Jan 18, 2024Roth MKMmainBuyBuy

About biote Corp.

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female. The company was founded in 2012 and is headquartered in Irving, Texas.

Sector
Healthcare
Industry
Medical Care Facilities
Country
United States
Website
biote.com

News

Your note

Sign in to keep a note on BTMD — it syncs with the Stock Master app.

Insider holders

BTMD insider holders
InsiderRelationLatest transactionDateShares held
BEER MARC DDirectorSaleJan 8, 20230
CONE STEPHEN MARKDirectorConversion of Exercise of derivative securityJun 29, 2023122,725
CONLON MARY ELIZABETHGeneral CounselSaleJul 4, 2023140,393
HEYER ANDREW RDirectorPurchaseJan 8, 20230
JACOBY DANA LYNNDirectorConversion of Exercise of derivative securityMay 20, 202450,970
KAMDAR SAMAR JAGATChief Financial OfficerPurchaseJan 8, 202313,000

Institution ownership

BTMD institution ownership
Holder% heldSharesValueReported
325 Capital Llc14.32%4,548,12726.33MSep 29, 2024
Bandera Partners LLC7.67%2,435,63514.10MSep 29, 2024
Blackrock Inc.5.44%1,725,8759.99MSep 29, 2024
Vanguard Group Inc4.47%1,417,7938.21MSep 29, 2024
Wasatch Advisors LP4.39%1,392,8098.06MSep 29, 2024
Dimensional Fund Advisors LP2.14%678,4593.93MSep 29, 2024

Fund ownership

BTMD fund ownership
Holder% heldSharesValueReported
Vanguard Total Stock Market Index Fund2.70%856,6034.96MSep 29, 2024
iShares Russell 2000 ETF2.12%673,5343.90MOct 30, 2024
Wasatch Micro-Cap Value Fund1.93%613,0103.55MSep 29, 2024
RBB Fund Inc.- Boston Partners Small Cap Value Fd II1.56%493,8622.86MSep 29, 2024
Vanguard Extended Market Index Fund1.08%342,0711.98MSep 29, 2024
Fidelity Small Cap Index Fund0.85%270,5401.57MAug 30, 2024
Advertisement